Cytek Enterprise Value Over E B I T D A from 2010 to 2024

CTKB Stock  USD 6.03  0.01  0.17%   
Cytek Biosciences' Enterprise Value Over EBITDA is decreasing over the years with slightly volatile fluctuation. Overall, Enterprise Value Over EBITDA is projected to go to -61.02 this year. From 2010 to 2024 Cytek Biosciences Enterprise Value Over EBITDA quarterly data regression line had arithmetic mean of  443.82 and r-squared of  0.66. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(64.23)
Current Value
(61.02)
Quarterly Volatility
259.85070339
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek main balance sheet or income statement drivers, such as Net Interest Income of 5.5 M, Interest Income of 8 M or Depreciation And Amortization of 9.7 M, as well as many exotic indicators such as Price To Sales Ratio of 6.07, Dividend Yield of 0.0 or PTB Ratio of 3.3. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
This module can also supplement Cytek Biosciences' financial leverage analysis and stock options assessment as well as various Cytek Biosciences Technical models . Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Latest Cytek Biosciences' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Cytek Biosciences over the last few years. It is Cytek Biosciences' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Cytek Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean443.82
Geometric Mean366.64
Coefficient Of Variation58.55
Mean Deviation222.73
Median610.86
Standard Deviation259.85
Sample Variance67,522
Range675
R-Value(0.81)
Mean Square Error24,451
R-Squared0.66
Significance0.0002
Slope(47.34)
Total Sum of Squares945,313

Cytek Enterprise Value Over E B I T D A History

2024 -61.02
2023 -64.23
2022 285.64
2021 236.46
2020 151.8

About Cytek Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytek Biosciences income statement, its balance sheet, and the statement of cash flows. Cytek Biosciences investors use historical funamental indicators, such as Cytek Biosciences's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may use each financial statement separately, they are all related. The changes in Cytek Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytek Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytek Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(64.23)(61.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for Cytek Stock analysis

When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stocks Directory
Find actively traded stocks across global markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is Cytek Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.658
Earnings Share
(0.09)
Revenue Per Share
1.497
Quarterly Revenue Growth
0.21
Return On Assets
(0.03)
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.